FONT-SIZE Plus   Neg

Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick Facts

Eli Lilly and Co. (LLY) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.

According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.

Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chipmaker Qualcomm is reportedly in talks with NXP Semiconductor NV (NXPI) for a possible acquisition, reports said. According to Bloomberg, negotiations are on with a probable price of $110 t $120 per NXP share. The deal would value NXP at around $34.7 billion. Regulators have confirmed the eleventh U.S. fatality linked to Takata Corp.'s defective air bag inflators. The National Highway Traffic Safety Administration or NHTSA said Thursday that a crash fatality in Riverside County, California, was tied to the rupture of a recalled Takata air bag inflator. Reynolds American Inc. (RAI) on Friday confirmed that British American Tobacco plc (BATS.L, BTI) has offered to buy the remaining 57.8 percent stake that it does not own in the US tobacco company for $47 billion. Reynolds said its board of directors will evaluate the offer, and respond accordingly to BAT, which currently owns 42.2 percent stake in Reynolds. The proposal represents an enterprise va
comments powered by Disqus
Follow RTT